BioMarin Pharmaceutical Inc. (BMRN)

85.02
0.49 0.57
NASDAQ : Health Technology
Prev Close 85.51
Open 85.39
Day Low/High 84.58 / 86.42
52 Wk Low/High 79.13 / 106.74
Volume 714.88K
Avg Volume 1.30M
Exchange NASDAQ
Shares Outstanding 179.07M
Market Cap 15.07B
EPS -0.40
P/E Ratio N/A
Div & Yield N.A. (N.A)
BioMarin Announces New England Journal Of Medicine Publishes Vosoritide Phase 2 Study Showing Sustained Annualized Growth Up To 42 Months In Children With Achondroplasia

BioMarin Announces New England Journal Of Medicine Publishes Vosoritide Phase 2 Study Showing Sustained Annualized Growth Up To 42 Months In Children With Achondroplasia

Company Announces Enrollment Met for 2-5 Year-Old Cohort in Separate Phase 2 Study in Infants and Young Children

BioMarin To Participate In Goldman Sachs 40th Annual Global Healthcare Conference On Tuesday, June 11 In Rancho Palos Verdes, CA

BioMarin To Participate In Goldman Sachs 40th Annual Global Healthcare Conference On Tuesday, June 11 In Rancho Palos Verdes, CA

SAN RAFAEL, Calif., June 5, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc.

BioMarin Announces Approval Of Vimizim® (elosulfase Alfa) In China For Treatment Of Morquio A Syndrome

BioMarin Announces Approval Of Vimizim® (elosulfase Alfa) In China For Treatment Of Morquio A Syndrome

First and Only Treatment in China Approved for Patients with This Ultra-Rare Genetic Condition

BioMarin Provides 3 Years Of Clinical Data From Ongoing Phase 1/2 Study Of Valoctocogene Roxaparvovec Gene Therapy For Severe Hemophilia A

BioMarin Provides 3 Years Of Clinical Data From Ongoing Phase 1/2 Study Of Valoctocogene Roxaparvovec Gene Therapy For Severe Hemophilia A

Substantial Reduction in excess of 92% in Mean Bleed Rate Requiring Factor VIII Infusions; Sustained over the Period of Observation (3 Years in High Dose and 2 Years in Low Dose)

BioMarin To Host Conference Call Tuesday, May 28, 2019 To Provide A Valoctocogene Roxaparvovec Phase 2 And Phase 3 Update

BioMarin To Host Conference Call Tuesday, May 28, 2019 To Provide A Valoctocogene Roxaparvovec Phase 2 And Phase 3 Update

SAN RAFAEL, Calif., May 27, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc.

BioMarin To Participate In 2019 RBC Capital Markets Global Healthcare Conference On May 21 In New York City

BioMarin To Participate In 2019 RBC Capital Markets Global Healthcare Conference On May 21 In New York City

SAN RAFAEL, Calif., May 16, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc.

2 Stocks You Definitely Should Consider Shorting This Week

2 Stocks You Definitely Should Consider Shorting This Week

These 'Bearish Bets' are showing both technical and quantitative deterioration.

A Big Biotech, an Online Apparel Retailer and Other Stocks That Look Good Short

BMRN, SFIX, INGR, VC and IQV all recently were downgraded by TheStreet's Quant Ratings.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AGTC, DCO, HAE, LILA, LILAK, NRT, RCII Downgrades: ANDE, BMRN, CCO, CLH, HCP, HGV, HIIQ, INGR, NCMI, NHTC Initiations: FEDU Read on to get TheStreet Quant Ratings' detailed report:

Here's How I'm Playing an Increasingly Volatile Market With These 2 Biotechs

Here's How I'm Playing an Increasingly Volatile Market With These 2 Biotechs

I am incrementally using buy-write option orders to add some shares to core holdings.

BioMarin To Participate In Bank Of America Merrill Lynch Health Care Conference On May 15 In Las Vegas

BioMarin To Participate In Bank Of America Merrill Lynch Health Care Conference On May 15 In Las Vegas

SAN RAFAEL, Calif., May 8, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc.

European Commission Approves Palynziq® (pegvaliase Injection) For Treatment Of Phenylketonuria (PKU) In Patients Aged 16 Years Or Older

European Commission Approves Palynziq® (pegvaliase Injection) For Treatment Of Phenylketonuria (PKU) In Patients Aged 16 Years Or Older

First Enzyme Substitution Therapy Approved in Europe to Treat the Underlying Cause of PKU in Patients Aged 16 Years or Older at Doses up to 60 mg

BioMarin Announces First Quarter 2019 Financial Results

BioMarin Announces First Quarter 2019 Financial Results

- Total Revenues Top $400 million in the Quarter

10 Speculative Stock Plays in the Biotech Sector

10 Speculative Stock Plays in the Biotech Sector

For investors interested in biotech, there's a lot to choose from, with options ranging from startups with potentially blockbuster new treatments to companies those that have been around the block a few times.

Forbes Names BioMarin 4th Best Midsize Employer In America

Forbes Names BioMarin 4th Best Midsize Employer In America

Company Ranks 1st Among Midsize Employers in 'Drugs & Biotechnology' Industry

BioMarin To Host First Quarter 2019 Financial Results Conference Call And Webcast On Thursday, April 25 At 4:30pm ET

BioMarin To Host First Quarter 2019 Financial Results Conference Call And Webcast On Thursday, April 25 At 4:30pm ET

SAN RAFAEL, Calif., April 2, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Becomes #3 Most Shorted Nasdaq 100 Component, Replacing Fiserv

BioMarin Pharmaceutical Becomes #3 Most Shorted Nasdaq 100 Component, Replacing Fiserv

The most recent short interest data has been released for the 03/15/2019 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

BioMarin To Participate In Cowen And Company 39th Annual Health Care Conference On March 12 In Boston

BioMarin To Participate In Cowen And Company 39th Annual Health Care Conference On March 12 In Boston

SAN RAFAEL, Calif., March 6, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc.

Behind The Seizure™ Program Expansion Helps Speed The Diagnosis Of Genetic Epilepsy In Younger Children Experiencing Unprovoked Seizures

Behind The Seizure™ Program Expansion Helps Speed The Diagnosis Of Genetic Epilepsy In Younger Children Experiencing Unprovoked Seizures

--Stoke Therapeutics and Xenon Pharmaceuticals Join Founders BioMarin and Invitae to Offer a No-Cost Epilepsy Gene Panel Testing Program for Children Up to 60 Months Who Have Had an Unprovoked Seizure--

Roche Deal for Spark Therapeutics Shows Biotech M&A Spark Hasn't Died

Roche Deal for Spark Therapeutics Shows Biotech M&A Spark Hasn't Died

Acquisition deals for biotech companies at the start of 2019 are giving the sector a nice boost; here are other names that could be merger candidates.

BioMarin Announces Full Year And Fourth Quarter 2018 Results

BioMarin Announces Full Year And Fourth Quarter 2018 Results

- Total Revenues for 2018 Grow 14% Year-over-Year to $1.5 Billion

BioMarin Pharmaceutical Becomes #2 Most Shorted Nasdaq 100 Component, Replacing Sirius XM Holdings

BioMarin Pharmaceutical Becomes #2 Most Shorted Nasdaq 100 Component, Replacing Sirius XM Holdings

The most recent short interest data has been released for the 01/31/2019 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

BioMarin Announces Ongoing Study Demonstrates Durable Treatment Benefit From Brineura® (cerliponase Alfa) For 3 Years

BioMarin Announces Ongoing Study Demonstrates Durable Treatment Benefit From Brineura® (cerliponase Alfa) For 3 Years

Reduced Rate of Decline Maintained in Children with CLN2 Disease, a Form of Batten Disease

BioMarin Announces 14 Presentations At 15th Annual WORLDSymposium™ 2019

BioMarin Announces 14 Presentations At 15th Annual WORLDSymposium™ 2019

Presentations to Highlight Results from Studies for the Treatment of Three Forms of MPS and CLN2 Disease, a Form of Batten Disease

BioMarin Pharmaceutical Becomes #3 Most Shorted Nasdaq 100 Component, Replacing Check Point Software Technologies

BioMarin Pharmaceutical Becomes #3 Most Shorted Nasdaq 100 Component, Replacing Check Point Software Technologies

The most recent short interest data has been released for the 01/15/2019 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

BioMarin Pharmaceutical Larger Than S&P 500 Component CBS Corp

BioMarin Pharmaceutical Larger Than S&P 500 Component CBS Corp

In the latest look at stocks ordered by largest market capitalization, Russell 3000 component BioMarin Pharmaceutical Inc. was identified as having a larger market cap than the smaller end of the S&P 500, for example CBS Corp , according to The Online Investor.

Two Small-Caps and One Mid-Cap Stock I Like So Far in 2019

Two Small-Caps and One Mid-Cap Stock I Like So Far in 2019

It has been a better year for the Russell 2000 and the small-caps it represents.

TheStreet Quant Rating: D+ (Sell)